Keryx Biopharma (KERX) Reports Zerenex Met Primary Endpoint in Phase 3
Tweet Send to a Friend
Keryx Biopharma (NASDAQ: KERX) announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
